✦ LIBER ✦

A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer

✍ Scribed by Michael S. Gordon; David Mendelson; Robert Carr; Raymond A. Knight; Rod A. Humerickhouse; Maria Iannone; Alison T. Stopeck

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 220 KB
Volume: 113
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.23953

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Toxicity report of a phase 1/2 dose-esca

Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy

✍ Samuel Bral; Michaël Duchateau; Harijati Versmessen; Douwe Verdries; Benedikt En 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 1 views